MediWound Ltd. addresses emergency demand for NexoBrid to treat the mass of burn casualty, caused by the war in Israel. Hospitals and military forces have urgently requested NexoBrid supplies. To address this critical need, MediWound has deployed all its available NexoBrid inventory to aid the substantial number of burn victims. MediWound remains committed to fulfilling its obligations to global markets and is implementing measures to ensure supply continuity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.24 USD | +3.28% | +15.66% | +79.35% |
Mar. 21 | MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 | CI |
Mar. 21 | Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.35% | 169M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- MDWD Stock
- News MediWound Ltd.
- MediWound Ltd. Deploys NexoBrid® for Emergency Supply